Dr Chris Davis

Research Associate (Virology)

Sir Michael Stoker Building, Garscube campus, 464 Bearsden Road, Glasgow, G61 1qh

Research interests

My research centres around emerging viral infections that pose significant threats to human and animal health. With the increased risk of transmission due to global travel, climate change, ecosystem alterations, my work focuses on new and emerging viruses. Using next-generation sequencing (NGS), I study viruses in East and West Africa (Uganda) and the UK. These include respiratory viruses such as COVID-19, Acute Hepatitis C virus (HCV), emerging viruses like Ebola and MPXV, and febrile viruses such as Crimean-Congo Haemorrhagic Fever (CCHF) and Lassa fever. My work aims to understand the complex nature of these viruses and develop effective strategies to limit spread. Currently, my work focuses primarily on understanding the underlying biology of MPXV.

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

Number of items: 62.

2023

Wallace, S. et al. (2023) Multiplexed biosensing of proteins and virions with disposable plasmonic assays. ACS Sensors, 8(9), pp. 3338-3348. (doi: 10.1021/acssensors.2c02238)

Pascall, D. J. et al. (2023) Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. Journal of Infection, 87(2), pp. 128-135. (doi: 10.1016/j.jinf.2023.05.019) (PMID:37270070) (PMCID:PMC10234362)

Pinto, R. M. et al. (2023) BTN3A3 evasion promotes the zoonotic potential of influenza A viruses. Nature, 619(7969), pp. 338-347. (doi: 10.1038/s41586-023-06261-8) (PMID:37380775)

Shepherd, J. G. , Davis, C. , Streicker, D. G. and Thomson, E. C. (2023) Emerging rhabdoviruses and human infection. Biology, 12(6), 878. (doi: 10.3390/biology12060878) (PMID:37372162) (PMCID:PMC10294888)

Ho, A. et al. (2023) Adeno-associated virus 2 infection in children with non-A-E hepatitis. Nature, 617(7961), pp. 555-563. (doi: 10.1038/s41586-023-05948-2) (PMID:36996873)

Pascall, D. J. et al. (2023) The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: a genomics-based retrospective cohort analysis. PLoS ONE, 18(4), e0284187. (doi: 10.1371/journal.pone.0284187) (PMID:37053201) (PMCID:PMC10101505)

Parker, E. et al. (2023) SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: an ISARIC4C prospective study. Frontiers in Immunology, 14, 1146702. (doi: 10.3389/fimmu.2023.1146702) (PMID:37056776) (PMCID:PMC10087108)

Liew, F. et al. (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 87, 104402. (doi: 10.1016/j.ebiom.2022.104402) (PMID:36543718) (PMCID:PMC9762734)

Turtle, L. et al. (2023) Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Medicine, 20(1), e1004086. (doi: 10.1371/journal.pmed.1004086) (PMID:36719907) (PMCID:PMC9928075)

Adesina, A. S. et al. (2023) Circulation of Lassa virus across the endemic Edo-Ondo axis, Nigeria, with cross-species transmission between multimammate mice. Emerging Microbes and Infections, 12(1), 2219350. (doi: 10.1080/22221751.2023.2219350) (PMID:37288752) (PMCID:PMC10251791)

Nickbakhsh, S. , McWilliam Leitch, E. C., Smith, S., Davis, C. , Hutchinson, S., Irving, W. L., McLauchlan, J. and Thomson, E. C. (2023) Geographical variation in Hepatitis C-related severe liver disease and patient risk factors: a multicentre cross-sectional study. Epidemiology and Infection, 151, e59. (doi: 10.1017/S0950268823000377) (PMID:36915219) (PMCID:PMC10126891)

2022

Vink, E. et al. (2022) Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study. Open Forum Infectious Diseases, 9(11), ofac531. (doi: 10.1093/ofid/ofac531) (PMID:36381618) (PMCID:PMC9619746)

Aranday-Cortes, E. et al. (2022) Real-world outcomes of direct-acting antiviral treatment and retreatment in United Kingdom–based patients infected with hepatitis C virus genotypes/subtypes endemic in Africa. Journal of Infectious Diseases, 226(6), pp. 995-1004. (doi: 10.1093/infdis/jiab110) (PMID:33668068) (PMCID:PMC9492310)

Shah, R. et al. (2022) Characterisation of a hepatitis C virus subtype 2a cluster in Scottish PWID with a suboptimal response to glecaprevir/pibrentasvir treatment. Viruses, 14(8), 1678. (doi: 10.3390/v14081678) (PMID:36016300) (PMCID:PMC9416734)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Dowell, A. C. et al. (2022) mRNA or ChAd0x1 COVID-19 vaccination of adolescents induces robust antibody and cellular responses with continued recognition of omicron following mRNA-1273. Frontiers in Immunology, 13, 882515. (doi: 10.3389/fimmu.2022.882515) (PMID:35720281) (PMCID:PMC9201026)

Knight, S. R. et al. (2022) Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 77(6), pp. 606-615. (doi: 10.1136/thoraxjnl-2021-217629) (PMID:34810237) (PMCID:PMC8610617)

Relph, K. A. et al. (2022) Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission. Open Forum Infectious Diseases, 9(5), ofac179. (doi: 10.1093/ofid/ofac179) (PMID:35531376) (PMCID:PMC9070482)

Närhi, F. et al. (2022) Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. Lancet Digital Health, 4(4), e220-e234. (doi: 10.1016/S2589-7500(22)00018-8) (PMID:35337642) (PMCID:PMC8940185)

Rosadas, C. et al. (2022) Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 302, 114475. (doi: 10.1016/j.jviromet.2022.114475) (PMID:35077719) (PMCID:PMC8782753)

Stockdale, A. J. et al. (2022) A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission. Journal of Viral Hepatitis, 29(4), pp. 252-262. (doi: 10.1111/jvh.13646) (PMID:35075742) (PMCID:PMC9305194)

Sullivan, M. K. et al. (2022) Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), pp. 271-284. (doi: 10.1093/ndt/gfab303) (PMID:34661677) (PMCID:PMC8788218)

Parry, H. et al. (2022) Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 15(1), 3. (doi: 10.1186/s13045-021-01219-7) (PMID:35000597) (PMCID:PMC8743056)

Dowell, A. C. et al. (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 23(1), pp. 40-49. (doi: 10.1038/s41590-021-01089-8) (PMID:34937928) (PMCID:PMC8709786)

2021

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Herder, V. et al. (2021) Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defences. PLoS Biology, 19(12), e3001065. (doi: 10.1371/journal.pbio.3001065) (PMID:34932557) (PMCID:PMC8765667)

Witkowska McConnell, W. et al. (2021) Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. Nature Communications, 12, 6994. (doi: 10.1038/s41467-021-27076-z) (PMID:34848705) (PMCID:PMC8632961)

Collier, D. A. et al. (2021) Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 596(7872), pp. 417-422. (doi: 10.1038/s41586-021-03739-1) (PMID:34192737) (PMCID:PMC8373615)

Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)

Davis, C. A. et al. (2021) Hepatitis E virus: whole genome sequencing as a new tool for understanding HEV epidemiology and phenotypes. Journal of Clinical Virology, 139, 104738. (doi: 10.1016/j.jcv.2021.104738) (PMID:33933822)

Gupta, R. K. et al. (2021) Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, 9(4), pp. 349-359. (doi: 10.1016/S2213-2600(20)30559-2) (PMID:33444539) (PMCID:PMC7832571)

Thomson, E. C. et al. (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184(5), 1171-1187.e20. (doi: 10.1016/j.cell.2021.01.037) (PMID:33621484) (PMCID:PMC7843029)

Rihn, S. J. et al. (2021) A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biology, 19(2), e3001091. (doi: 10.1371/journal.pbio.3001091) (PMID:33630831) (PMCID:PMC7906417)

Bangura, U. et al. (2021) Lassa virus circulation in small mammal populations in Bo District, Sierra Leone. Biology, 10(1), 28. (doi: 10.3390/biology10010028) (PMID:33466234) (PMCID:PMC7824740)

Da Silva Filipe, A. et al. (2021) Genomic epidemiology reveals multiple introductions of SARS-CoV-2 from mainland Europe into Scotland. Nature Microbiology, 6(1), pp. 112-122. (doi: 10.1038/s41564-020-00838-z) (PMID:33349681)

Parker, M. D. et al. (2021) Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. Genome Research, 31, pp. 645-658. (doi: 10.1101/gr.268110.120) (PMID:33722935) (PMCID:PMC8015849)

2020

Gilbert, M. et al. (2020) Distemper, extinction and vaccination of the Amur tiger. Proceedings of the National Academy of Sciences of the United States of America, 117(50), pp. 31954-31962. (doi: 10.1073/pnas.2000153117) (PMID:33229566) (PMCID:PMC7749280)

Davis, C. et al. (2020) Postexposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the United Kingdom: an operational, safety, and immunogenicity report. Clinical Infectious Diseases, 71(11), pp. 2872-2879. (doi: 10.1093/cid/ciz1165) (PMID:31784751) (PMCID:PMC7778350)

Knight, S. R. et al. (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. British Medical Journal, 2020, 370. (doi: 10.1136/bmj.m3339) (PMID:32907855)

Swann, O. V. et al. (2020) Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. British Medical Journal, 370, m3249. (doi: 10.1136/bmj.m3249) (PMID:32960186) (PMCID:PMC7488201)

Bradshaw, D. et al. (2020) Transmission of hepatitis C virus in HIV‐positive and PrEP‐using MSM in England. Journal of Viral Hepatitis, 27(7), pp. 721-730. (doi: 10.1111/jvh.13286) (PMID:32115809)

Childs, K., Cannon, M., Davis, C. , Thomson, E. C. , Dusheiko, G. and Agarwal, K. (2020) Reply to: “Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action”. Journal of Hepatology, 72(3), pp. 585-586. (doi: 10.1016/j.jhep.2019.11.010) (PMID:31870568)

2019

Childs, K. et al. (2019) Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C. Journal of Hepatology, 71(6), pp. 1099-1105. (doi: 10.1016/j.jhep.2019.07.025) (PMID:31400349)

Baylis, S. A. et al. (2019) Development of a World Health Organization International Reference Panel for different genotypes of hepatitis E virus for nucleic acid amplification testing. Journal of Clinical Virology, 119, pp. 60-67. (doi: 10.1016/j.jcv.2019.05.006) (PMID:31431408)

Jerome, H. et al. (2019) Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. Journal of Infection, 79(4), pp. 383-388. (doi: 10.1016/j.jinf.2019.08.003) (PMID:31398374) (PMCID:PMC6859916)

Ankcorn, M. et al. (2019) Convalescent plasma therapy for persistent hepatitis E virus infection. Journal of Hepatology, 71(2), pp. 434-438. (doi: 10.1016/j.jhep.2019.04.008) (PMID:31075322)

Davis, C. et al. (2019) New highly diverse hepatitis C strains detected in sub‐Saharan Africa have unknown susceptibility to direct‐acting antiviral treatments. Hepatology, 69(4), pp. 1426-1441. (doi: 10.1002/hep.30342) (PMID:30387174) (PMCID:PMC6492010)

2017

Briggs, L. C., Chan, A.W. E., Davis, C. A. , Whitelock, N., Hotiana, H. A., Baratchian, M., Bagnéris, C., Selwood, D. L., Collins, M. K. and Barrett, T. E. (2017) IKKγ mimetic peptides block the resistance to apoptosis associated with KSHV infection. Journal of Virology, 91(23), e01170-17. (doi: 10.1128/JVI.01170-17) (PMID:28931678) (PMCID:PMC5686756)

Hedegaard, D. L. et al. (2017) High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease. Journal of Hepatology, 66(1), pp. 28-38. (doi: 10.1016/j.jhep.2016.07.048) (PMID:27531641) (PMCID:PMC5558612)

2016

Donald, C. L. et al. (2016) Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil. PLoS Neglected Tropical Diseases, 10(10), e0005048. (doi: 10.1371/journal.pntd.0005048) (PMID:27706161) (PMCID:PMC5051680)

Baratchian, M., Davis, C. A. , Shimizu, A., Escors, D., Bagnéris, C., Barrett, T. and Collins, M. K. (2016) Distinct activation mechanisms of NF-κB regulator inhibitor of NF-κB kinase (IKK) by isoforms of the cell death regulator cellular FLICE-like inhibitory protein (cFLIP). Journal of Biological Chemistry, 291(14), pp. 7608-7620. (doi: 10.1074/jbc.M116.718122) (PMID:26865630) (PMCID:PMC4817188)

2015

Mailly, L. et al. (2015) Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nature Biotechnology, 33(5), pp. 549-554. (doi: 10.1038/nbt.3179) (PMID:25798937) (PMCID:PMC4430301)

2012

Davis, C. , Harris, H. J., Hu, K., Drummer, H. E., McKeating, J. A., Mullins, J. G.L. and Balfe, P. (2012) In silico directed mutagenesis identifies the CD 81/claudin‐1 hepatitis C virus receptor interface. Cellular Microbiology, 14(12), pp. 1892-1903. (doi: 10.1111/cmi.12008) (PMID:22897233) (PMCID:PMC3549482)

Farquhar, M. J., Hu, K., Harris, H. J., Davis, C. , Brimacombe, C. L., Fletcher, S. J., Baumert, T. F., Rappoport, J. Z., Balfe, P. and McKeating, J. A. (2012) Hepatitis C virus induces CD81 and claudin-1 endocytosis. Journal of Virology, 86(8), pp. 4305-4316. (doi: 10.1128/JVI.06996-11) (PMID:22318146) (PMCID:PMC3318669)

2011

Lupberger, J. et al. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine, 17(5), pp. 589-595. (doi: 10.1038/nm.2341) (PMID:21516087) (PMCID:PMC3938446)

2010

Fletcher, N. F. et al. (2010) Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology, 139(4), 1365-1374.e2. (doi: 10.1053/j.gastro.2010.06.008) (PMID:20538002) (PMCID:PMC3298458)

Harris, H. J. et al. (2010) Claudin association with CD81 defines hepatitis C virus entry. Journal of Biological Chemistry, 285(27), pp. 21092-21102. (doi: 10.1074/jbc.M110.104836) (PMID:20375010) (PMCID:PMC2898367)

Krieger, S. E. et al. (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology, 51(4), pp. 1144-1157. (doi: 10.1002/hep.23445) (PMID:20069648)

Davis, C. , Harris, H. J. and McKeating, J. A. (2010) The involvement of tight junction protein claudin-1 in hepatitis C virus entry. In: Yu, A. S.L. (ed.) Claudins. Series: Current topics in membranes (65). Academic Press, pp. 273-292. ISBN 9780123810397 (doi: 10.1016/S1063-5823(10)65012-0)